Revance Therapeutics, Inc FDA Record

Summary

Revance Therapeutics, Inc Form 483s

2 Form 483s published by FDA.

A Form 483 lists the observations FDA investigators made at the end of an inspection. FDA publishes some Form 483s in its reading room, and each date links to that document. Read the observations with the FDA 483 search.

Recent FDA inspections

2 inspections from Feb 27, 2025 to May 1, 2025.

NAI

No objectionable conditions or practices were found during the inspection.

VAI

Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

OAI

Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

FDA-inspected facilities

2 inspected sites, newest inspection first.

Revance Therapeutics, Inc and the FDA: common questions

Has Revance Therapeutics, Inc received an FDA warning letter?

No FDA warning letter addressed to the name "Revance Therapeutics, Inc" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has Revance Therapeutics, Inc received an FDA Form 483?

FDA has published 2 Form 483s for Revance Therapeutics, Inc in its reading room, the most recent dated Jul 15, 2022. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect Revance Therapeutics, Inc?

The most recent FDA inspection on file ended May 1, 2025 at Moffett Field, CA and was classified NAI. FDA has 2 inspections of Revance Therapeutics, Inc on file.